XOMA Royalty Corporation (XOMA) - Total Assets

Latest as of December 2025: $272.70 Million USD

Based on the latest financial reports, XOMA Royalty Corporation (XOMA) holds total assets worth $272.70 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of XOMA Royalty Corporation for net asset value and shareholders' equity analysis.

XOMA Royalty Corporation - Total Assets Trend (1985–2025)

This chart illustrates how XOMA Royalty Corporation's total assets have evolved over time, based on quarterly financial data.

XOMA Royalty Corporation - Asset Composition Analysis

Current Asset Composition (December 2025)

XOMA Royalty Corporation's total assets of $272.70 Million consist of 43.0% current assets and 57.0% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 30.4%
Accounts Receivable $4.90 Million 1.8%
Inventory $0.00 0.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $44.76 Million 16.4%
Goodwill $0.00 0.0%

Asset Composition Trend (1985–2025)

This chart illustrates how XOMA Royalty Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XOMA market cap.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: XOMA Royalty Corporation's current assets represent 43.0% of total assets in 2025, a decrease from 60.4% in 1985.
  • Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 57.1% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 1985.
  • Asset Diversification: The largest asset category is intangible assets at 16.4% of total assets.

XOMA Royalty Corporation Competitors by Total Assets

Key competitors of XOMA Royalty Corporation based on total assets are shown below.

Company Country Total Assets
Synlogic Inc
NASDAQ:SYBX
USA $15.45 Million
Entero Therapeutics, Inc.
NASDAQ:GRDX
USA $135.37 Million
Vyome Holdings, Inc.
NASDAQ:HIND
USA $7.05 Million
Applied Therapeutics Inc
NASDAQ:APLT
USA $34.37 Million
Cellectar Biosciences Inc
NASDAQ:CLRB
USA $14.98 Million
Intensity Therapeutics, Inc. Common stock
NASDAQ:INTS
USA $12.29 Million
TNF Pharmaceuticals, Inc.
NASDAQ:TNFA
USA $17.15 Million
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
USA $3.07 Million

XOMA Royalty Corporation - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.37 5.15 5.36
Quick Ratio 3.37 5.15 5.20
Cash Ratio 0.00 0.00 0.00
Working Capital $82.44 Million $101.23 Million $57.14 Million

XOMA Royalty Corporation - Advanced Valuation Insights

This section examines the relationship between XOMA Royalty Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.06
Latest Market Cap to Assets Ratio 1.85
Asset Growth Rate (YoY) 23.2%
Total Assets $272.70 Million
Market Capitalization $505.19 Million USD

Valuation Analysis

Above Book Valuation: The market values XOMA Royalty Corporation's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: XOMA Royalty Corporation's assets grew by 23.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for XOMA Royalty Corporation (1985–2025)

The table below shows the annual total assets of XOMA Royalty Corporation from 1985 to 2025.

Year Total Assets Change
2025-12-31 $272.70 Million +23.24%
2024-12-31 $221.28 Million -5.56%
2023-12-31 $234.30 Million +66.90%
2022-12-31 $140.38 Million -15.72%
2021-12-31 $166.56 Million +32.95%
2020-12-31 $125.28 Million +30.88%
2019-12-31 $95.72 Million +50.07%
2018-12-31 $63.78 Million +41.95%
2017-12-31 $44.94 Million +56.69%
2016-12-31 $28.68 Million -61.70%
2015-12-31 $74.88 Million -16.46%
2014-12-31 $89.63 Million -33.50%
2013-12-31 $134.78 Million +27.54%
2012-12-31 $105.68 Million +35.42%
2011-12-31 $78.04 Million +5.10%
2010-12-31 $74.25 Million +40.56%
2009-12-31 $52.82 Million -21.36%
2008-12-31 $67.17 Million -20.80%
2007-12-31 $84.81 Million -7.28%
2006-12-31 $91.48 Million +26.04%
2005-12-31 $72.58 Million +56.89%
2004-12-31 $46.26 Million -61.08%
2003-12-31 $118.85 Million +65.57%
2002-12-31 $71.78 Million -16.64%
2001-12-31 $86.11 Million +90.45%
2000-12-31 $45.21 Million +59.76%
1999-12-31 $28.30 Million -24.13%
1998-12-31 $37.30 Million -42.44%
1997-12-31 $64.80 Million +12.31%
1996-12-31 $57.70 Million +41.08%
1995-12-31 $40.90 Million -34.46%
1994-12-31 $62.40 Million -33.69%
1993-12-31 $94.10 Million -13.91%
1992-12-31 $109.30 Million -29.16%
1991-12-31 $154.30 Million +59.07%
1990-12-31 $97.00 Million -12.22%
1989-12-31 $110.50 Million +100.91%
1988-12-31 $55.00 Million -17.29%
1987-12-31 $66.50 Million +40.30%
1986-12-31 $47.40 Million +218.12%
1985-12-31 $14.90 Million --

About XOMA Royalty Corporation

NASDAQ:XOMA USA Biotechnology
Market Cap
$505.19 Million
Market Cap Rank
#12562 Global
#2994 in USA
Share Price
$41.65
Change (1 day)
-0.41%
52-Week Range
$22.89 - $42.00
All Time High
$45.61
About

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with co… Read more